A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Filters
Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer
2019
PLoS Computational Biology
Preserved Fulltext
Here, we report a previously unrecognized behavior in heterogeneous tumors: cooperative adaptation to therapy (CAT), in which cancer cells induce co-resistant phenotypes in neighboring cancer cells when ...
Using a CRISPR/Cas9 toolkit we engineered phenotypically diverse non-small cell lung cancer (NSCLC) cells by conferring mutations in Dicer1, a type III cytoplasmic endoribonuclease involved in small non-coding ...
Acknowledgments The authors would like to thank Dr. Jeff Gore and Dr. ...
doi:10.1371/journal.pcbi.1007278
pmid:31449515
pmcid:PMC6709889
fatcat:3btkgpyngzgw5bfzzbwq6zh6te
Tracheostomy protocol compliance: Herding cats?*
2008
Critical Care Medicine
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Pharmacologic preconditioning with levosimendan is currently known to represent a powerful cell-protective mechanism conferring relative resistance against cell death. ...
Cooper et al. ...
Tables 1 and 2 provide my current opinions on use of steroid therapy in ARDS and septic shock, respectively. R. Phillip Dellinger, MD, FCCM Cooper Health Systems -Critical Care Section Camden, NJ ...
doi:10.1097/ccm.0b013e3181761228
pmid:18520651
fatcat:a7js773jyrdpjn25oafe7xsiaa
The role of memory in non-genetic inheritance and its impact on cancer treatment resistance
2021
PLoS Computational Biology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
We study the role of phenotypic heterogeneity in a drug-resistant, genetically homogeneous population of non-small cell lung cancer cells to derive a rational treatment schedule that drives population ...
Consequently, understanding the role of this plasticity in treatment resistance and failure is a key component of improving cancer therapy. ...
Acknowledgments Portions of this work were completed while TC, DN, and ARAA participated in the thematic semester in Mathematical Biology at the Institut Mittag-Leffler. ...
doi:10.1371/journal.pcbi.1009348
pmid:34460809
pmcid:PMC8432806
fatcat:kx6yovmdx5byzbpy7r3h7hdsii
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
2019
Cell Reports
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
We performed genome-scale loss-of-function CRISPR-Cas9 screens in the presence of a MEK1/2 inhibitor (MEKi) in KRAS-mutant pancreatic and lung cancer cell lines and identified genes that cooperate with ...
cancer cells. ...
SHOC2 confers a selectively potent sensitization of KRAS mutant lung cancer cells to MEKi. ...
doi:10.1016/j.celrep.2019.08.090
pmid:31577942
pmcid:PMC6918830
fatcat:ttlatrftrraybo7dbs72uiljbq
Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors
2015
Cancer Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
This resistance mechanism was documented in non-small cell lung cancer and gastric cancer cells with MET amplification. ...
Protein synthesis was increased in drug-resistant cells, secondary to a Pim-mediated increase in cap-independent translation. ...
Further work will be needed to determine the cooperative role Pim activation plays with other genetic and genomic alterations to induce resistance to MET inhibitors in lung, gastric, and other cancers. ...
doi:10.1158/0008-5472.can-15-0544
pmid:26670562
pmcid:PMC4683614
fatcat:7yoxer4x6zh6thh5u6uqp4k4xq
Concomitant Diffuse Pulmonary Carcinoma and Chronic Interstitial Pneumonia in a Cat with Hypertrophic Cardiomyopathy: Unusual Pathological Findings and Differential Diagnosis
2017
Journal of Comparative Pathology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
To the best of our knowledge, this is the first description of an esophageal embryonal rhabdomyosarcoma in a dog.
NOTES ...
Embryonal rhabdomyosarcomas occur in 23% of canine cases and are most commonly reported in the head and neck region. ...
Introduction: In human breast cancer, Phosphatidylinositol-3 kinase (PI3K) mutation is involved in tumour growth and resistance to hormone therapy. ...
doi:10.1016/j.jcpa.2016.11.220
fatcat:uqdkroslvfewbo4vugk5beuhji
Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors
2014
American Journal of Cancer Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
The aim of this study was to examine the effect of 20 single nucleotide polymorphisms (SNPs) in 20 oxidative stress-related genes on clinical outcome in 219 patients with advanced non-small cell lung cancer ...
Many types of cancer have high antioxidant capacity that effectively scavenges reactive oxygen species and thus protect cancer cells against oxidative damage. ...
Approximately 85% of lung cancers are non-small cell lung cancer (NSCLC) [2] . An activating mutation of epidermal growth factor receptor (EGFR) is present in 40.9% of NSCLC [3] . ...
pmid:25520881
pmcid:PMC4266725
fatcat:izqj7jyhjrbddpyxycgrriwsee
Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
2020
Molecular Cancer Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
RNAi knockdown of CXCR7 inhibited proliferation in trametinib resistant cells. Thus, adaptive resistance to chronic trametinib treatment contributes to proliferation in the presence of the drug. ...
Adaptive followed by acquired gene expression changes contributed to proliferation in trametinib resistant cells, suggesting inhibition of early transcriptional reprogramming could prevent resistance and ...
Deep sequencing and the development of molecular subtypes have improved initial diagnosis, but tumors can carry pre-existing secondary mutations that confer resistance to therapy, leading to non-durable ...
doi:10.1158/1541-7786.mcr-19-1011
pmid:32753473
pmcid:PMC7642176
fatcat:xis573nzrfaepgwwqaorbkpkj4
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
2017
Current Medicinal Chemistry
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
CSCs are a small population of tumor cells that possess the stem cell property and initiate, drive carcinogenesis contributing to tumor cellular heterogeneity [93][94][95]. Many cancers Zhou et al. ...
CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1, also known as CXCL12), which has been found to be expressed in more than 23 different types of cancers. ...
ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013; 328(1):144-151. [PubMed: 22935675] 102. ...
doi:10.2174/0929867324666170830111531
pmid:28875842
pmcid:PMC5949083
fatcat:5ans3i6xcvcufmhekx73boi3iq
Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma
2022
Cells
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
Melanoma cells are notorious for their high plasticity and ability to switch back and forth between various melanoma cell states, enabling the adaptation to sub-optimal conditions and therapeutics. ...
This phenotypic plasticity, which has gained more attention in cancer research, is proposed as a new paradigm for melanoma progression. ...
Cells 2022, 11, 1157 ...
doi:10.3390/cells11071157
pmid:35406721
pmcid:PMC8997563
fatcat:i2p747s2mfa2jmnixboxrqzdea
The role of memory in non-genetic inheritance and its impact on cancer treatment resistance
[article]
2021
bioRxiv
pre-print
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
We further use our model to study the role of phenotypic heterogeneity in therapeutic resistance in a genetically identical non-small cell lung cancer population. ...
We study the role of phenotypic heterogeneity in a drug-resistant, genetically homogeneous population of non-small cell lung cancer cells to derive a rational treatment schedule that drives population ...
therapies to prevent phenotypic switching.
224
Avoiding resistance to therapy in NSCLC
225
226
non-small cell lung cancer (NSCLC) accounts for 20% of all cancer-related deaths [50]. 227
Nearly ...
doi:10.1101/2021.02.22.431869
fatcat:oxb4xxbizndatmlwxcqljt6rgy
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
2020
Trends in Cancer
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
We also highlight recent evidence describing how therapy-induced TCS can impact cancer stem cell (CSC) expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity. ...
Understanding how cancer cells overcome chemotherapy-induced cell death is critical in promoting patient survival. ...
Disclaimer Statement A.M.G. and A.S. are cofounders, directors, and shareholders of Cell Stress Discoveries, Ltd. ...
doi:10.1016/j.trecan.2020.02.020
pmid:32460003
fatcat:ahizim2tf5cglhmks3hbl43tlq
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies
2016
Cancer Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32. 2. Figure 2. Validation of variation in RTK bypass resistance capacity. ...
therapies in lung carcinoma (6-10). ...
This work was supported by NIH 1-DP5-OD019815-01 to A.S.M. and in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute. ...
doi:10.1158/0008-5472.can-16-0123
pmid:27450453
pmcid:PMC5026573
fatcat:4x6zq5jf7nfnbopfnyq3k24kqe
The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies
2020
Antioxidants
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Constant change by acquired mutations and metabolic reprogramming contribute to the high inter- and intratumor heterogeneity of malignant cells, their selective growth advantage, and their resistance to ...
While cancer cells often produce more ROS due to their increased growth-favoring demands, numerous conventional anticancer therapies exploit this feature to ensure selective cancer cell death triggered ...
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer 2019, 134, 42-45. [CrossRef] 56. ...
doi:10.3390/antiox9111151
pmid:33228209
pmcid:PMC7699519
fatcat:k7xylmadsvgzxommhnayucb2pi
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
2020
Cancers
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Secondary resistant mutations in cancer cells arise in response to certain small molecule inhibitors. These mutations inevitably cause recurrence and often progression to a more aggressive form. ...
The Catalogue of Somatic Mutations in Cancer (COSMIC) produced a compendium of resistant mutations to small molecule inhibitors reported in the literature. ...
Acknowledgments: We thank James and Ellen Bazzoli for their generous donation to sponsor our laboratory.
Conflicts of Interest: The authors declare no conflict of interest. ...
doi:10.3390/cancers12040927
pmid:32283832
pmcid:PMC7226513
fatcat:pvujprxicjgang3gwyivfojicy
« Previous
Showing results 1 — 15 out of 2,052 results